This trial is evaluating whether Dexrazoxane Hydrochloride will improve 2 primary outcomes, 16 secondary outcomes, and 10 other outcomes in patients with T Acute Lymphoblastic Leukemia. Measurement will happen over the course of Up to 6 months.
This trial requires 475 total participants across 3 different treatment groups
This trial involves 3 different treatments. Dexrazoxane Hydrochloride is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Mopal is the most aggressive and complicated disease with an annual incidence of approximately 0.3/100,000 population. Because of this low incidence, the clinical course of Mopal is not predictable." - Anonymous Online Contributor
"MPAL seems to be clinically very similar to B-CLL. The distinction between both disorders is based on the molecular/cytogenetic features; MPAL seems to be more inclined to the "classic" M-CLL subtype, while B-CLL is related to the more advanced subtypes. This differentiation is important since MPAL is considered a neoplastic disease, while B-CLL is not.\n" - Anonymous Online Contributor
"The presence of mcl1 translocation is strongly associated with a poor response to imatinib therapy in patients with chronic myeloid leukemia and should be added to a stratification of patients with advanced chronic myeloid leukemia treated with imatinib. Findings from a recent study identifies mcl1 as the molecular basis of leukemic progression in patients with advanced chronic myeloid leukemia." - Anonymous Online Contributor
"Many types of chemotherapy are used in the treatment of childhood leukemia. A majority of patients who qualify for this study will receive a course of chemotherapy at the main pediatric oncology center at UGM." - Anonymous Online Contributor
"The cause of mPal is unknown. This may be due to the fact that the diagnosis and pathologic work-up of these cases are limited and that the disease frequently presents with an array of signs and symptoms." - Anonymous Online Contributor
"Around 1400 cases (30% of all hematologic malignancy cases) are diagnosed with (MPAL/CMML/CPAL/MPAL-like)/B-CML-CPAL annually in the United States. MPAL is rarely seen outside of the United States." - Anonymous Online Contributor
"Low dose methylprednisolone is both safe and effective in a group of people with malignancies presenting with acute or chronic leukemia (n = 25) and may represent a beneficial role in combination with other antineoplastic drugs (n=16)." - Anonymous Online Contributor
"Findings from a recent study suggest that methylprednisolone is the most frequently used glucocorticoid in adults with MPAL. Interestingly, the combination with prednisone is relatively infrequent compared with other combinations. However, this combination is potentially more effective than single therapy when the patient has received a minimum of two treatment cycles." - Anonymous Online Contributor
"MPAL is a subtype of acute myeloid leukemia associated with an increased risk of bleeding and death. It is therefore important to control for these risks as part of clinical treatment by use of a corticosteroid such as MP." - Anonymous Online Contributor
"Methylprednisolone can be used with success in most patients with relapsing CML, but in some patients it has been ineffective. It has been shown to be helpful in the treatment of B-CLL patients, but the results are disappointing, and the exact mechanisms are still unclear. Because of its short-term benefits and low toxicity, there are cases in which long-term use of methylprednisolone is warranted. In a recent study, findings of new studies are very promising and will provide new information on the use of steroids." - Anonymous Online Contributor
"Methylprednisolone does not change blood cell counts, but induces a rapid rise in blood cell counts following the medication. A rapid rise in neutrophils and lymphocytes after methylprednisolone treatment can interfere with detection of sub-clinical myelodysplastic syndromes (MDS) in the marrow. Methylprednisolone should be avoided if the patient has other features that indicate a need for a splenectomy." - Anonymous Online Contributor
"Methylprednisolone was associated with adverse treatment-related side effects and low overall QOL scores. However, it may have a positive effect on the quality of life for those with mpa." - Anonymous Online Contributor